INTRODUCTION — While most patients with heart failure (HF), with either reduced or preserved ejection fraction, have low or normal cardiac output accompanied by elevated systemic vascular resistance, a minority of patients with HF present with a high-output state with low systemic vascular resistance.
This topic will discuss the causes and pathophysiology of high-output HF. Clinical manifestations, diagnosis, and management of high-output HF are discussed separately. The diagnosis and management of HF with reduced ejection fraction and HF with preserved ejection fraction are discussed separately. (See "Determining the etiology and severity of heart failure or cardiomyopathy" and "Overview of the management of heart failure with reduced ejection fraction in adults" and "Heart failure with preserved ejection fraction: Clinical manifestations and diagnosis" and "Treatment and prognosis of heart failure with preserved ejection fraction".)
EPIDEMIOLOGY — High-output HF is an uncommon type of HF. The prevalence of this disorder is uncertain, particularly since the potential contributory role of high-output syndromes to HF may not be appreciated in many cases. Although high-output states are uncommon as a sole cause of HF, they may more commonly contribute to HF in patients with underlying cardiovascular disease and reduced myocardial reserve. (See 'Role of concurrent cardiac conditions' below.)
In a Mayo Clinic series of 120 consecutive patients with high-output HF diagnosed between 2000 and 2014, the most common causes were morbid obesity (31 percent), liver disease (22.5 percent), arteriovenous shunts (22.5 percent), lung disease (16 percent), and myeloproliferative disorders (8 percent) [1]. This study excluded patients with physiologic (eg, pregnancy, fever, infection), iatrogenic (pulmonary vasodilator or inotrope administration), or congenital causes of high output, as well as patients with severe anemia (hemoglobin <8 mg/dL), hyperthyroidism, valvular heart disease, constrictive pericarditis, left ventricular systolic dysfunction (left ventricular ejection fraction <45 percent), cardiomyopathy, or heart transplantation.
PATHOPHYSIOLOGY — High-output HF is characterized by elevated cardiac output, low systemic vascular resistance (due to peripheral vasodilation or arteriovenous shunting), and low arterial-venous oxygen content difference; some types are associated with increased oxygen consumption (reflecting increased metabolic demand). In the setting of high-output HF, the elevation in cardiac output is greater than that required to meet metabolic demand [1].
In high-output HF, low systemic vascular resistance results in borderline preserved or depressed systemic arterial blood pressure and elevated cardiac filling pressures [1]. Ineffective blood volume and pressure lead to activation of the sympathetic nervous system and renin-angiotensin-aldosterone axis and increased serum vasopressin (antidiuretic hormone) concentrations. This neurohormonal activation results in increased renovascular resistance and reduced renal blood flow and glomerular filtration rate, with retention of salt and water [2]. Chronic volume overload gradually may cause ventricular enlargement, remodeling, and HF.
The conditions that provoke high-output HF are rarely the sole cause of HF. In most such patients, the high cardiac output provokes HF in the setting of reduced ventricular reserve (systolic and/or diastolic dysfunction) from some underlying cardiac problem. Thus, the presence of high-output HF should prompt a search for another underlying cardiovascular condition. (See 'Role of concurrent cardiac conditions' below and "Clinical manifestations, diagnosis, and management of high-output heart failure", section on 'Diagnostic evaluation'.)
CAUSES AND THEIR MECHANISMS — A number of conditions lead to an obligatory increase in cardiac output, which can precipitate HF in some patients [1,3]. While hemodynamic alterations are present across various etiologies, there are some differences among etiologies. In a series of 120 consecutive patients with high-output HF, oxygen consumption indexed to weight was highest and mixed venous oxygen content was lowest in the myeloproliferative disorder group [1]. The subgroup with liver disease had the lowest arterial-venous oxygen content difference and lowest systemic vascular resistance.
There are a variety of pathophysiologic processes that result in a high-output state. Some causes appear to have primarily peripheral vascular effects, while other causes may have metabolic effects or myocardial as well as peripheral vascular effects. The distinction between these categories is imperfect, since some causes are associated with combinations of peripheral vascular, metabolic, and myocardial effects (eg, hyperthyroidism). Peripheral vascular effects can have secondary effects on cardiac structure and function.
The prognosis of high-output HF is highly variable, as it is largely dependent upon the cause and concurrent conditions. Overall, the mortality rate in patients with high-output HF is increased compared with controls without heart disease (eg, hazard ratio 3.4; 95% CI 1.6-7.6 compared with controls [1]).
Causes grouped by predominant mechanism
Peripheral vascular effects — The following conditions with largely peripheral vascular primary effects can lead to high-output HF. Peripheral vascular effects can lead to cardiac volume overload.
Morbid obesity — High-output HF in obese patients appears to be related to vasodilation, but the mechanism for vasodilation is unclear [1]. Although oxygen consumption is high in this setting, it is not elevated after adjustment for weight. The effects of obesity on the cardiovascular system may be exacerbated by pressure overload states such as hypertension [4]. Some data suggest that leptin may contribute to plasma volume expansion as well as eccentric ventricular dilatation and hypertrophy that is seen in high-output states [5].
Arteriovenous fistula — A large or multiple small systemic arteriovenous fistulas can cause high-output HF. A fistula can be congenital or acquired. Blood from a high-pressure artery is shunted via the arteriovenous fistula to a low-pressure vein, thus bypassing capillary beds and decreasing systemic vascular resistance. Compensatory increases in heart rate, stroke volume, and total plasma volume ensue. The elevation in cardiac output associated with a fistula depends upon the size of the communication and the magnitude of the resultant reduction in systemic vascular resistance. Since blood flowing through the fistula bypasses the capillary circulation, the total cardiac output increases by the quantity of blood flowing through the fistula to maintain capillary perfusion.
As described below, high-output HF in patients with chronic kidney disease most often results from an arteriovenous dialysis fistula and anemia (which is now less common due to the widespread use of erythropoietin) superimposed on underlying heart disease. Other renal etiologies include acquired intrarenal arteriovenous fistulas such as those arising as a complication following renal biopsy, renal cell carcinoma, and congenital renal arteriovenous malformation [6,7].
Acquired — Acquired fistulas may be caused by trauma, by a medical procedure (eg, surgically constructed arteriovenous access for hemodialysis or as a complication of a procedure), or by a highly vascular condition or tumor. Traumatic causes include bullet or knife wounds, especially in the thigh. An aortocaval fistula may be caused by trauma or by spontaneous rupture of an aortic aneurysm [8,9].
Iatrogenic fistulas include surgically constructed arteriovenous fistulas used for access to the circulation in patients undergoing chronic hemodialysis [10-12]. An arteriovenous fistula can cause high-output HF and can also worsen pulmonary hypertension and cause right HF, as discussed separately. Removal of unused arteriovenous fistulae following renal transplant may be beneficial in this setting [13]. (See "Evaluation and management of heart failure caused by hemodialysis arteriovenous access" and "Pulmonary hypertension in patients with end-stage kidney disease".)
A renal arteriovenous fistula is a complication of renal biopsy, although a symptomatic fistula causing high-output HF is rare. Other cases of iatrogenic arteriovenous fistulas associated with high-output failure include an iliac arteriovenous fistula after lumbar disk surgery [14] or abdominal surgery [15] and high-output failure following transjugular intrahepatic portosystemic shunting (TIPS) [16]. In a prospective study of 15 portal hypertensive patients, hyperdynamic circulation worsened immediately after TIPS, with a progressive adaptation over two months [17].
Arterial puncture for cardiac catheterization is an uncommon iatrogenic cause of arteriovenous fistula with an incidence of less than 1 percent of catheterizations with a transfemoral approach [18,19] and less than 0.1 percent using a transradial or transulnar approach [20,21]. High-output HF is a rare sequela of an arteriovenous fistula from cardiac catheterization with a clinical presentation ranging from two days to several months post-catheterization [22].
Skeletal disorders such as osteitis deformans (Paget disease) [23], multiple myeloma [24-26], and polyostotic fibrous dysplasia (McCune-Albright syndrome) have been identified as causes of high-output HF. Multiple minute arteriovenous fistulas in the bony lesions may cause high-output HF [26]. Extensive bone involvement (more than 20 percent of the skeleton) is required to increase the cardiac output to the point at which it may contribute to high-output problems. An additional factor for the increase in cardiac output in Paget disease may be increased cutaneous blood flow resulting from local heat production by the increased metabolic activity of affected bone. There appears to be a linear relationship between the amount of skeletal involvement and cardiac index in patients with this disease. In one study, the subgroup of patients with more extensive skeletal involvement had lower peripheral vascular resistance, higher stroke volume, and greater hydroxyproline excretion (a marker of bone turnover) [27]. (See "Clinical manifestations and diagnosis of Paget disease of bone" and "Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis" and "Definition, etiology, and evaluation of precocious puberty", section on 'McCune-Albright syndrome'.)
High-output HF with acquired arteriovenous fistula(s) may also be caused by a highly vascular condition or tumor such as Paget disease, Wilms' tumor [28], renal cell carcinoma [29,30], or giant placental chorioangioma [31]. Clinical manifestations of these conditions are discussed further separately. (See "Presentation, diagnosis, and staging of Wilms tumor" and "Clinical manifestations, evaluation, and staging of renal cell carcinoma".)
Congenital — Congenital arteriovenous fistulas range from small cutaneous hemangiomas to large channel communications that can distort a limb [32]. A minority of patients with congenital fistulas have giant or multiple hemangiomas, which cause HF [33,34]. (See "Hepatic hemangioma" and "Congenital hemangiomas: Rapidly involuting congenital hemangioma (RICH), noninvoluting congenital hemangioma (NICH), and partially involuting congenital hemangioma (PICH)" and "Infantile hemangiomas: Epidemiology, pathogenesis, clinical features, and complications".)
Hepatic hemangiomas are typically found incidentally, with larger lesions (4 cm) more likely to present with symptoms such as abdominal pain, right upper quadrant discomfort, or fullness. Hepatic hemangiomas rarely cause high-output failure either in the setting of innumerable hemangiomas (known as hepatic hemangiomatosis) or in the setting of a giant hemangioma. Cutaneous hemangiomas may be a marker for hepatic hemangiomas. (See "Hepatic hemangioma".)
Hereditary hemorrhagic telangiectasia (HHT or Osler-Weber-Rendu disease) is characterized by hemorrhagic telangiectasias involving the mucous membranes (causing epistaxis and gastrointestinal bleeding) and skin (eg, lips, fingertips). In approximately 15 percent of afflicted individuals, arteriovenous malformations occur in the lung and may be associated with massive hemoptysis [35,36]. Some patients with hepatic involvement develop clinically significant arteriovenous shunts and high-output failure [37-41]. In some patients, high-output HF is the first manifestation of the disease [37]. Additional clinical manifestations include unexplained hematuria, hemoptysis, or family history of bleeding. (See "Clinical manifestations and diagnosis of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)".)
Giant cutaneous hemangiomas can also promote the development of high-output failure [42,43]. Hemangiomas are the most common tumors of infancy and seldom cause more than a cosmetic problem. Fifty percent of cutaneous lesions are present at birth; the remainder usually surface by two months of age. In rare cases, high-flow arteriovenous shunting in giant or multiple cutaneous hemangiomas can lead to the development of high-output failure [33,42,44,45]. (See "Infantile hemangiomas: Epidemiology, pathogenesis, clinical features, and complications".)
Cirrhosis — Cirrhosis is associated with progressive systemic vasodilation (particularly splanchnic) and the development of intrahepatic or mesenteric arteriovenous shunts which cause increased cardiac output and low blood pressure. In a study of patients prior to liver transplantation, cirrhosis was associated with reductions in end-systolic elastance, arterial elastance, and ventriculoarterial coupling [46]. Others have shown elevated B-type natriuretic peptide levels [47]. Signs of reduced tissue perfusion include low urinary sodium excretion and increased plasma levels of the "hypovolemic" hormones renin, aldosterone, and vasopressin [48-50]. Intrapulmonary arteriovenous shunting is also observed in some patients [51]. The development of cardiac failure is insidious in these patients [52], but most die from hepatic failure prior to symptomatic heart disease. (See "Cirrhosis in adults: Overview of complications, general management, and prognosis", section on 'Complications of portal hypertension' and "Hyponatremia in patients with cirrhosis", section on 'Pathogenesis'.)
Erythroderma — Erythroderma is a clinical presentation of a wide range of cutaneous and systemic diseases (including psoriasis and drug hypersensitivity reactions). The elevated cardiac output results from substantial cutaneous dilatation and an increase in blood flow to the skin. Peripheral vasodilation associated with shunting of blood flow through the skin may result in high-output HF. (See "Erythroderma in adults".)
Carcinoid syndrome — High-output HF (with low systemic vascular resistance and high cardiac output) is an atypical cardiovascular manifestation of carcinoid syndrome, which more commonly causes HF via right heart valve fibrosis [53,54]. (See "Clinical features of carcinoid syndrome" and "Carcinoid heart disease".)
Metabolic effects — The following conditions result in increased metabolic demand that may drive increases in cardiac output:
Myeloproliferative disorders — Myeloproliferative disorders (eg, myelofibrosis, polycythemia vera, and leukemia) with extramedullary hematopoiesis may cause a hypermetabolic state with increased oxygen consumption and decreased systemic vascular resistance [1]. Some patients with myelofibrosis have isolated right HF, which may be caused by the effects of circulating progenitor cells on right ventricular and pulmonary vascular function.
Hyperthyroidism — Hyperthyroidism causes high-output HF by a combination of metabolic, vascular, and direct myocardial effects. Thyroid hormone is a potent regulator of whole body metabolism; an increased circulating level of thyroxine produces an increase in metabolism accompanied by a reduction in systemic vascular resistance and an obligatory increase in cardiac output [55-58]. Hyperthyroidism may create a hyperdynamic circulatory state via enhanced sympathoadrenal activation [56,59] as well as by direct action of thyroid hormone, which possesses strong, positive chronotropic and inotropic effects [60,61]. The heart rate is increased and pulse pressure is widened. The metabolic and circulatory changes in hyperthyroid individuals are similar to those in normal volunteers during epinephrine infusion [56]. Administration of sympatholytic agents such as beta blockers to patients with hyperthyroidism can decrease the heart rate, cardiac output, and pulse pressure toward normal [56]. However, sympatholytic agents alone do not completely normalize cardiac parameters in these patients. (See "Cardiovascular effects of hyperthyroidism".)
Among patients with hyperthyroidism and HF, left ventricular ejection fraction (LVEF) may be preserved or reduced. LV systolic dysfunction may be due to tachycardia-mediated cardiomyopathy (eg, atrial fibrillation with a rapid ventricular response) or concomitant cardiac disease [62,63]. Chronic volume overload, hypercontractility, and tachycardia contribute to the development of cardiac hypertrophy in patients with hyperthyroidism [56,62,64]. It has been postulated that hyperthyroidism may have a cardiotoxic effect, perhaps mediated by beta-adrenergic stimulation [62]. Direct activation of protein-synthesizing processes by thyroid hormone may also contribute to myocardial hypertrophy. Patients with hyperthyroidism have an abnormally low or absent increase in LVEF in response to exercise [65-67]. Hyperthyroidism can also cause a hyperdynamic right ventricle that normalizes following treatment to restore a euthyroid state [68]. Reversible right ventricular failure and pulmonary hypertension has also been reported [69]. (See "Epidemiology of and risk factors for atrial fibrillation" and "Cardiovascular effects of hyperthyroidism", section on 'Heart failure' and "Arrhythmia-induced cardiomyopathy".)
Myocardial and peripheral vascular effects — The following conditions are postulated as having peripheral vascular effects as well as possible direct myocardial effects that may lead to high-output HF.
Sepsis — Sepsis, a clinical syndrome caused by a dysregulated inflammatory response to infection, is associated with a spectrum of hemodynamic alterations: there is frequently initial hypovolemia (prior to fluid resuscitation) with varying alterations in systemic vascular resistance and cardiac output [70,71]. Low systemic vascular resistance is frequently accompanied by high cardiac output, but patients with sepsis with HF often have reversible systolic and/or diastolic LV and/or right ventricular dysfunction, which limits cardiac reserve [70,71].
Infection leads to an inflammatory response, releasing tumor necrosis factor-alpha, interleukin-1-beta, Il-6, and other proinflammatory cytokines. These lead to systemic vasodilation and may decrease cardiac contractility via inducible nitric oxide synthase [72,73].
Beriberi — Beriberi heart disease is due to severe thiamine (vitamin B1) deficiency. The mechanism for high-output failure in beriberi may be multifactorial, with high cardiac output superimposed on myocardial dysfunction. Thiamine deficiency initially presents as a high-output state secondary to vasodilation and an increase in blood volume [74]; this is followed by eventual depression of myocardial function and the development of a low-output state [75]. The high cardiac output is due to reduced systemic vascular resistance and augmented venous return. It is not totally clear what causes the marked reduction in systemic vascular resistance, but it may reflect direct vasomotor depression [74].
Postmortem gross examination of the heart shows dilation without other changes. Histopathologic study shows nonspecific changes, including myocardial vacuolization and interstitial myocardial edema in the early stages, with myocyte hypertrophy, fibrosis, and cellular infiltration in the chronic phase [76]. Cardiac magnetic resonance imaging may be used to demonstrate myocardial edema in severe thiamine deficiency [77].
A biochemical lesion due to thiamine deficiency may contribute to high output and myocardial dysfunction in beriberi [78,79]. Pyruvate and lactate are important substrates for oxidation and energy production in heart muscle, but thiamine deficiency blocks their utilization. Specifically, thiamine pyrophosphate is needed for the decarboxylation of pyruvate and its subsequent oxidation in the citric acid cycle. As a result of thiamine deficiency, pyruvate and its precursor lactate build up in the blood; increased blood lactate level has been used in the diagnosis of beriberi but is nonspecific. Thiamine deficiency also inhibits the function of the hexose monophosphate shunt, contributing to insufficient oxygenation of the tissues. (See "Overview of water-soluble vitamins".)
Acromegaly — Growth hormone is important for the maintenance of normal cardiac function [80]. HF is not uncommon in newly diagnosed acromegaly [81] (see "Causes and clinical manifestations of acromegaly"). In a review of 102 such patients, 10 had overt HF at the time of diagnosis [82]. Compared with those without HF, these patients had an increase in LV mass index that was largely due to chamber dilation, a reduction in LVEF (42 versus 66 percent), and a significant elevation in cardiac index (4.3 versus 3.5 L/min per m2 versus 3.1 L/min per m2 in controls). A contemporary, multinational registry of over 3000 patients reported low rates of cardiovascular complications (<5 percent) in adults with newly diagnosed acromegaly [83]. (See "Causes and clinical manifestations of acromegaly".)
Mitochondrial diseases — Mitochondrial diseases are a cause of high-output failure associated with lactic acidosis, reduced systemic vascular resistance caused by disturbed oxidative metabolism, and cardiomyopathy [84,85]. (See "Mitochondrial myopathies: Clinical features and diagnosis".)
Anagrelide — Anagrelide, a phosphodiesterase III inhibitor used in the treatment of essential thrombocythemia [86], has been identified as a cause of high-output HF. Anagrelide may cause vasodilation and may also have positive inotropic and chronotropic effects. Case reports of cardiomyopathy secondary to anagrelide have also been reported [87].
Other
Anemia — Anemia has been identified as a cause of high-output HF (eg, in patients with beta-thalassemia intermedia [88,89]), but the mechanism of HF in anemia is not completely understood. Anemia, even when severe, rarely causes HF, and when it does, it is likely that the high-output failure is superimposed upon some cardiac abnormality such as valvular heart disease or underlying LV dysfunction [90]. In a seminal study involving right heart catheterization, normal cardiac hemodynamics were maintained in patients with hemoglobin values as low as 7 g/dL [91]. When the hemoglobin was 5 to 7 g/dL, cardiac output increased and HF did not occur. HF developed in the absence of underlying heart disease only with severe anemia (ie, hemoglobin less than 5 g/dL).
Decreased LV afterload secondary to reduced serum viscosity may play a role [92]. Anemia may also cause peripheral vasodilation [93] due to endothelial dysfunction [94]. The loss of hemoglobin is partly compensated for by an increase in cardiac output and widening of the arteriovenous O2 difference. Thus, severe anemia can result in LV volume overload and increased stroke volume that can alter LV function [92]. As an example, one study of serial echocardiograms in 124 patients with sickle cell anemia found progressive chamber enlargement and increased LV mass [95]. Moreover, the LV systolic time interval and the LV pre-ejection period were progressively higher in the sickle cell group compared with same-aged controls, suggesting a decline in LV function with time.
Chronic anemia may also contribute to the development of HF from other causes. In patients with HF due to other causes, there is evidence that chronic anemia is associated with the progression of HF, but anemia is also associated with a number of common comorbidities. There is conflicting evidence regarding whether anemia is an independent cause of HF progression and worse outcomes, or if it is simply associated with overall disease severity. (See "Evaluation and management of anemia and iron deficiency in adults with heart failure".)
Chronic pulmonary disease — Chronic pulmonary disease with associated hypoxia and hypercapnia is associated with high-output HF, which may be caused by reduced systemic vascular resistance, salt and water retention, and impaired renal blood flow [1]. Some patients with high-output HF associated with lung disease present with isolated right HF, which may be secondary to hypoxic pulmonary vasoconstriction with systemic arterial vasodilation [1].
Additional precipitants of high output — There are a number of physiologic conditions that can substantially increase cardiac output and contribute to a high-output state that may precipitate HF:
●Physical or emotional stress – Stress may provoke a state of catecholamine excess with increased cardiac output and variable effects on systemic vascular resistance.
●Exercise – With exercise, cardiac output increases, and systemic vascular resistance generally decreases. (See "Exercise physiology".)
●Fever – Fever increases metabolic demand and produces vasodilation, especially in the skin. Resolution of the fever is accompanied by a reduction in cardiac output to normal.
●Hot climate – A hot, and especially humid, environment increases cardiac output through mechanisms similar to fever [96].
●Pregnancy is associated with increased metabolic demand, increased blood volume, placental blood flow (which may act as an arteriovenous shunt), reduced systemic vascular resistance, elevated maternal heart rate (by 15 to 20 beats per minute), and increased resting cardiac output (by 30 to 50 percent above baseline). (See "Maternal adaptations to pregnancy: Cardiovascular and hemodynamic changes".)
These hemodynamic changes may precipitate HF in pregnant women with an underlying cardiac disorder. Women with an underlying cause for a high cardiac output, such as an arteriovenous fistula, hereditary telangiectasia, or anemia, are more likely to develop high-output HF during pregnancy [97-100]. In addition, multiple pregnancies in a patient with underlying fistulas may progressively exacerbate vascular malformations and lead to the development of HF despite a history of previous uncomplicated pregnancies. (See "Management of heart failure during pregnancy".)
Role of concurrent cardiac conditions — Causes contributing to high cardiac output are rarely the sole cause of HF; in most patients with high-output HF, HF is provoked by high output in the setting of reduced ventricular reserve (systolic and/or diastolic dysfunction) from some underlying cardiac problem. Thus, the presence of high-output HF should prompt a search for another underlying cardiovascular condition, including a search for acquired arteriovenous fistulas.
In some clinical settings, multiple factors may contribute to the development of HF. As an example, in patients with end-stage kidney disease who have high-output HF related to hemodialysis, arteriovenous access, anemia (which is now less common due to the widespread use of erythropoietin), and volume expansion (due to salt and water retention) caused by kidney disease may contribute to the high-output state. Premature atherosclerosis and LV hypertrophy due to hypertension are common in patients with end-stage kidney disease. Thus, patients with end-stage kidney disease frequently have heart disease with increased susceptibility to HF in the setting of an elevated cardiac output. Another example of multiple factors causing HF is high-output HF caused by the combination of morbid obesity plus cirrhosis due to nonalcoholic fatty liver disease. (See "Evaluation and management of heart failure caused by hemodialysis arteriovenous access" and "Overview of screening and diagnosis of heart disease in patients on dialysis".)
SUMMARY AND RECOMMENDATIONS
●High-output heart failure (HF) is an uncommon type of HF. The prevalence of this disorder is uncertain, particularly since the potential contributory role of high-output syndromes to HF may not be appreciated in many cases. Although high-output states are uncommon as a sole cause of HF, they may more frequently contribute to HF in patients with underlying cardiovascular disease and reduced myocardial reserve. (See 'Epidemiology' above.)
●High-output HF is characterized by elevated cardiac output, low systemic vascular resistance (due to peripheral vasodilation or arteriovenous shunting), and low arterial-venous oxygen content difference; some types are associated with increased oxygen consumption (reflecting increased metabolic demand). In the setting of high-output HF, the elevation in cardiac output is greater than that required to meet metabolic demand. (See 'Pathophysiology' above.)
●There are a variety of pathophysiologic processes that result in a high-output state. Some causes appear to have primarily peripheral vascular effects, while other causes may have metabolic effects or myocardial as well as peripheral vascular effects. The distinction between these categories is imperfect since some causes are associated with combinations of peripheral vascular, metabolic, and myocardial effects (eg, hyperthyroidism, beriberi). Peripheral vascular effects can have secondary effects on cardiac structure and function. (See 'Causes and their mechanisms' above.)
•Morbid obesity, arteriovenous fistula, cirrhosis, erythroderma, and carcinoid syndrome are among the causes of high-output HF with peripheral vascular effects. (See 'Peripheral vascular effects' above.)
•Myeloproliferative disorders and hyperthyroidism are causes of high-output HF associated with increased metabolic demand.
•Sepsis, beriberi, acromegaly, and mitochondrial diseases are causes of high-output HF with myocardial and peripheral vascular effects.
•Other causes of high-output HF include anemia and chronic pulmonary disease.
●Pregnancy is associated with increased metabolic demand, increased blood volume, and placental blood flow (which may act as an arteriovenous shunt); reduced systemic vascular resistance; elevated maternal heart rate (by 15 to 20 beats per minute); and increased resting cardiac output (by 30 to 50 percent above baseline). These hemodynamic changes may precipitate HF in pregnant women with an underlying cardiac disorder. (See "Maternal adaptations to pregnancy: Cardiovascular and hemodynamic changes".)
1 : High-Output Heart Failure: A 15-Year Experience.
2 : High-output heart failure revisted
3 : High Output Cardiac Failure.
4 : Diet-induced obesity promotes altered remodeling and exacerbated cardiac hypertrophy following pressure overload.
5 : Leptin-Aldosterone-Neprilysin Axis: Identification of Its Distinctive Role in the Pathogenesis of the Three Phenotypes of Heart Failure in People With Obesity.
6 : Symptomatic intrarenal arteriovenous fistula detected 25 years after percutaneous renal biopsy.
7 : Congestive heart failure in a hypertensive patient (don't forget the stethoscope).
8 : Aortocava fistula: experience with five patients.
9 : High-output heart failure resulting from chronic aortocaval fistula.
10 : High-output heart failure: how to define it, when to treat it, and how to treat it.
11 : Cardiac safety in vascular access surgery and maintenance.
12 : Cardiorenal syndrome in renal transplant recipients - It's the fistula at fault: A case series.
13 : Removal of Noninfected Arteriovenous Fistulae after Kidney Transplantation is a Safe and Beneficial Management Strategy for Unused Dialysis Access.
14 : Arteriovenous fistula as a complication of lumbar disc surgery: case report.
15 : Two cases of high-output heart failure as initial presentation of iliac arteriovenous fistula.
16 : High-output congestive heart failure following transjugular intrahepatic portal-systemic shunting.
17 : Haemodynamic adaptation two months after transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients.
18 : Incidence and outcome of femoral vascular complications among 18,165 patients undergoing cardiac catheterisation.
19 : Incidence and clinical outcome of iatrogenic femoral arteriovenous fistulas: implications for risk stratification and treatment.
20 : Safety and feasibility of transulnar versus transradial artery approach for coronary catheterization in non-selective patients.
21 : Vascular Complications Following Transradial and Transulnar Coronary Angiography in 1600 Consecutive Patients.
22 : Congestive heart failure secondary to an arteriovenous fistula from cardiac catheterization and angioplasty.
23 : Morbidity and mortality associated with Paget's disease of bone: a population-based study.
24 : Reversible high-output cardiac failure, an unusual marker of disease status in multiple myeloma.
25 : Prevalence and clinical characteristics of a high cardiac output state in patients with multiple myeloma.
26 : Arteriovenous shunting in patients with multiple myeloma and high-output failure.
27 : Assessment of cardiac function by echocardiography in Paget's disease of bone.
28 : Hyperdynamic heart failure due to A-V fistula associated with Wilms' tumor.
29 : Arteriovenous fistulae secondary to renal cell carcinoma. Clinical and cardiovascular manifestations: report of a case.
30 : Digging deep: high output heart failure in renal cell carcinoma.
31 : Giant chorioangiomas: perinatal outcomes and techniques in fetoscopic devascularization.
32 : Congenital arteriovenous anomalies of the limbs.
33 : Congestive heart failure with diffuse neonatal hemangiomatosis--case report and literature review.
34 : Scalp congenital hemangioma with associated high-output cardiac failure in a premature infant: Case report and review of literature.
35 : Pulmonary arteriovenous malformations. A state of the art review.
36 : Pulmonary arteriovenous fistula: presentation, diagnosis, and treatment.
37 : High out-put congestive heart failure as first manifestation of Osler-Weber-Rendu disease.
38 : Osler-Weber-Rendu disease with multiple intrahepatic arteriovenous fistulas.
39 : Hereditary hemorrhagic telangiectasia, liver vascular malformations and cardiac consequences.
40 : Reported cardiac phenotypes in hereditary hemorrhagic telangiectasia emphasize burdens from arrhythmias, anemia and its treatments, but suggest reduced rates of myocardial infarction.
41 : Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist's perspective.
42 : Severe congestive heart failure in newborns due to giant cutaneous hemangiomas.
43 : Congenital cutaneous hemangioma causing cardiac failure: a case report and review of the literature.
44 : Successful transcutaneous arterial embolization of a giant hemangioma associated with high-output cardiac failure and Kasabach-Merritt syndrome in a neonate: a case report.
45 : Large multifocal cutaneous hemangioma along lines of Blaschko with cardiac failure treated with propranolol.
46 : Effect of ventriculo-arterial coupling on transplant outcomes in cirrhotics: Analysis of pressure-volume curve relations.
47 : Cardiac hemodynamic profiles and pro-B-type natriuretic Peptide in cirrhotic patients undergoing liver transplantation.
48 : Pathophysiology of portal hypertension.
49 : Cirrhotic cardiomyopathy.
50 : Water and sodium retention in edematous disorders: role of vasopressin and aldosterone.
51 : Echocardiographic detection of intrapulmonary shunting in a patient with hepatopulmonary syndrome: case report and review of the literature.
52 : Pathophysiological and clinical approach to cirrhotic cardiomyopathy.
53 : Metastatic carcinoid disease presenting solely as high-output heart failure.
54 : Cardiovascular abnormalities in patients with a carcinoid syndrome.
55 : Thyrotoxicosis-induced congestive heart failure in an urban hospital.
56 : Thyroid hormone and the cardiovascular system.
57 : Echocardiographic LV function in thyrotoxicosis.
58 : Hyperthyroidism: a "curable" cause of congestive heart failure--three case reports and a review of the literature.
59 : The hemodynamic and metabolic interrelationships in the activity of epinephrine, norepinephrine and the thyroid hormones.
60 : Action of thyroid hormone on the transmembrane potentials from sinoatrial node cells and atrial muscle cells in isolated atria of rabbits.
61 : Effect of thyroxine on ventricular myocardial contractility and ATPase activity in guinea pigs.
62 : Incidence, clinical characteristics and outcome of congestive heart failure as the initial presentation in patients with primary hyperthyroidism.
63 : Mechanisms in endocrinology: Heart failure and thyroid dysfunction.
64 : Early abnormalities of left ventricular myocardial characteristics associated with subclinical hyperthyroidism.
65 : Abnormal left ventricular function in hyperthyroidism: evidence for a possible reversible cardiomyopathy.
66 : Cardiac performance in thyrotoxicosis: analysis of 10 untreated patients.
67 : Cardiovascular hemodynamics and exercise tolerance in thyroid disease.
68 : Hyperdynamic Right Heart Function in Graves' Hyperthyroidism Measured by Echocardiography Normalises on Restoration of Euthyroidism.
69 : Acute Right Ventricular Heart Failure: An Uncommon Case of Thyrotoxicosis.
70 : Understanding cardiac failure in sepsis.
71 : Characterization of cardiac dysfunction in sepsis: an ongoing challenge.
72 : Sepsis and the heart.
73 : Nitric Oxide Synthase 1 Modulates Basal andβ-Adrenergic-Stimulated Contractility by Rapid and Reversible Redox-Dependent S-Nitrosylation of the Heart.
74 : Hemodynamic studies in beriberi heart disease.
75 : The challenge of cardiomyopathy.
76 : The haemodynamic, histopathological and hormonal features of alcoholic cardiac beriberi.
77 : Cardiovascular magnetic resonance in wet beriberi.
78 : Thiamin deficiency and heart failure: the current knowledge and gaps in literature.
79 : Wet beriberi with multiple organ failure remarkably reversed by thiamine administration: A case report and literature review.
80 : GH and the cardiovascular system: an update on a topic at heart.
81 : Assessment of the awareness and management of cardiovascular complications of acromegaly in Italy. The COM.E.T.A. (COMorbidities Evaluation and Treatment in Acromegaly) Study.
82 : High output heart failure in patients with newly diagnosed acromegaly.
83 : Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database.
84 : Refractory high output heart failure in a patient with primary mitochondrial respiratory chain disease.
85 : High-output heart failure in mitochondrial myopathy: a fulminant form with severe lactic acidosis and rhabdomyolysis.
86 : High-output heart failure associated with anagrelide therapy for essential thrombocytosis.
87 : A Case of Anagrelide-Induced Nonischemic Cardiomyopathy in a Patient With Essential Thrombocythemia.
88 : Heart disease in thalassemia intermedia: a review of the underlying pathophysiology.
89 : Cardiovascular function and treatment inβ-thalassemia major: a consensus statement from the American Heart Association.
90 : Pathophysiology of anemia in heart failure.
91 : THE CARDIAC OUTPUT IN PATIENTS WITH CHRONIC ANEMIA AS MEASURED BY THE TECHNIQUE OF RIGHT ATRIAL CATHETERIZATION.
92 : Pathophysiology of anaemia: focus on the heart and blood vessels.
93 : High output heart failure.
94 : Associations between endothelial dysfunction and clinical and laboratory parameters in children and adolescents with sickle cell anemia.
95 : Cardiac size and function in children with sickle cell anemia.
96 : Human circulatory and thermoregulatory adaptations with heat acclimation and exercise in a hot, dry environment.
97 : High-output heart failure due to a renal arteriovenous fistula in a pregnant woman with suspected preeclampsia.
98 : High-output heart failure due to hepatic arteriovenous fistula during pregnancy: a case report.
99 : An arteriovenous malformation in pregnancy: a case report and review of the literature.
100 : Hereditary telangiectasia and multiple pulmonary arteriovenous fistulas. Clinical deterioration during pregnancy.